Ganfule

GFL capsule exerts a protective effect against ALD in mice and hepatocytes, potentially through the inhibition of inflammation, oxidative stress and apoptosis. This study provides a solid theoretical foundation for the potential application of GFL capsule in the prevention and clinical management of ALD.

Molecular docking analysis, molecular dynamics simulation, and in vitro experiments suggest that quercetin (QCT) mediates its effects through specifically binding to IL6 and STAT3, resulting in the subsequent inhibition of the IL6/STAT3 signaling pathway. This study elucidates the pharmacological mechanism of GFL in treating AFB1-induced toxic liver injury, providing theoretical evidence for its clinical application.

This study confirms the protective effect of GFL on liver injury and shows that GFL inhibits glutamine metabolism, which was correlated with the NF-κB pathway, and eventually alleviates liver fibrosis. These results are conducive to the development of new therapeutic drugs for liver fibrosis.

This study is the first to report the anti-HCC effect of GFL associated with gut microbiota and plasma metabolites. GFL may improve the gut microbiota structure, such as increasing probiotics - Lactobacillus. It also provides a new strategy for the scientific demonstration of the modernization of traditional Chinese medicine.